Kamada (KMDA) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Kamada is set to release its Q2 2025 earnings on August 13, with analysts expecting earnings of $0.09 per share and revenue of $158.59 million.
• The company's stock opened at $6.85 and has seen a 1-year price range between $5.17 and $9.15, reflecting its volatile performance.
• Institutional investors have recently increased their stakes in Kamada, with significant investments from firms like Goldman Sachs Group and Jane Street Group totaling over $1 million in new stakes.

Kamada (NASDAQ:KMDA - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $158.59 million for the quarter. Kamada has set its FY 2025 guidance at EPS.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. The company had revenue of $44.02 million during the quarter, compared to analyst estimates of $154.06 million. Kamada had a net margin of 9.60% and a return on equity of 6.31%. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Trading Up 1.0%

KMDA traded up $0.07 during midday trading on Friday, hitting $7.12. 33,212 shares of the company traded hands, compared to its average volume of 49,646. The business has a 50 day simple moving average of $7.40 and a two-hundred day simple moving average of $7.05. Kamada has a 52-week low of $5.17 and a 52-week high of $9.15. The company has a market capitalization of $409.47 million, a price-to-earnings ratio of 24.55, a PEG ratio of 0.85 and a beta of 0.93.

Institutional Investors Weigh In On Kamada

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in Kamada during the 1st quarter valued at about $582,000. Goldman Sachs Group Inc. acquired a new position in shares of Kamada during the 1st quarter worth approximately $497,000. Cubist Systematic Strategies LLC acquired a new position in shares of Kamada during the 1st quarter worth approximately $206,000. Finally, NewEdge Advisors LLC grew its position in shares of Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 28,165 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KMDA has been the topic of a number of research reports. Sidoti raised shares of Kamada to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 21st. Finally, Benchmark restated a "buy" rating and issued a $15.00 target price on shares of Kamada in a research report on Thursday, May 15th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.